Aryl hydrocarbon receptor in association with RelA modulates IL-6 expression in non-smoking lung cancer

Oncogene

Volumn 31, Issue 20, 2012, Pages 2555-2565

  Chen, P H ^a,b   Chang, H ^c,d   Chang, J T ^a,e   Lin, P ^a,b  

^a CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

^b NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

^e CHUNG SHAN MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

AhR; IL 6; lung adeno carcinoma; NFkB; non smokers

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 3 (4 TERT BUTYLPHENYLSULFONYL) 2 PROPENENITRILE; AROMATIC HYDROCARBON RECEPTOR; INTERLEUKIN 6; PROTEIN P50; TRANSCRIPTION FACTOR RELA;

ARTICLE; CANCER PATIENT; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOSOL; DISEASE ASSOCIATION; FEMALE; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CELL NUCLEUS; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-6; LUNG NEOPLASMS; MALE; RECEPTORS, ARYL HYDROCARBON; SMOKING; TRANSCRIPTION FACTOR RELA; TRANSCRIPTIONAL ACTIVATION;

EID: 84861369598     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.438     Document Type: Article

References (57)

1. Aggarwal BB. (2004). Nuclear factor-kappaB: the enemy within. Cancer Cell 6: 203-208.
2. Ando M, Wakai K, Seki N, Tamakoshi A, Suzuki K, Ito Y et al. (2003). Attributable and absolute risk of lung cancer death by smoking status: findings from the Japan Collaborative Cohort Study. Int J Cancer 105: 249-254. (Pubitemid 36505329)
3. Arenzana-Seisdedos F, Turpin P, Rodriguez M, Thomas D, Hay RT, Virelizier JL et al. (1997). Nuclear localization of I kappa B alpha promotes active transport of NF-kappa B from the nucleus to the cytoplasm. J Cell Sci 110(Part 3): 369-378. (Pubitemid 27095656)
4. Barouki R, Coumoul X, Fernandez-Salguero PM. (2007). The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 581: 3608-3615. (Pubitemid 47080995)
5. Bryant A, Cerfolio RJ. (2007). Differences in epidemiology, histology, and survival between cigarette smokers and never-smokers who develop non-small cell lung cancer. Chest 132: 185-192. (Pubitemid 47068220)
6. Camacho IA, Singh N, Hegde VL, Nagarkatti M, Nagarkatti PS. (2005). Treatment of mice with 2,3,7,8-tetrachlorodibenzo-pdioxin leads to aryl hydrocarbon receptor-dependent nuclear translocation of NF-kappaB and expression of Fas ligand in thymic stromal cells and consequent apoptosis in T cells. J Immunol 175: 90-103. (Pubitemid 40884305)
7. Carolan BJ, Harvey BG, De BP, Vanni H, Crystal RG. (2008). Decreased expression of intelectin 1 in the human airway epithelium of smokers compared to nonsmokers. J Immunol 181: 5760-5767.
8. Chang JT, Chang H, Chen PH, Lin SL, Lin P. (2007a). Requirement of aryl hydrocarbon receptor overexpression for CYP1B1 upregulation and cell growth in human lung adenocarcinomas. Clin Cancer Res 13: 38-45. (Pubitemid 46121850)
9. Chang LW, Chang YC, Ho CC, Tsai MH, Lin P. (2007b). Increase of carcinogenic risk via enhancement of cyclooxygenase-2 expression and hydroxyestradiol accumulation in human lung cells as a result of interaction between BaP and 17-beta estradiol. Carcinogenesis 28: 1606-1612. (Pubitemid 47241812)
10. Chen CL, Hsu LI, Chiou HY, Hsueh YM, Chen SY, Wu MM et al. (2004a). Ingested arsenic, cigarette smoking, and lung cancer risk: a follow-up study in arseniasis-endemic areas in Taiwan. JAMA 292: 2984-2990.
11. Chen J, Yan Y, Li J, Ma Q, Stoner GD, Ye J et al. (2005). Differential requirement of signal pathways for benzo[a]pyrene (B[a]P)-induced nitric oxide synthase (iNOS) in rat esophageal epithelial cells. Carcinogenesis 26: 1035-1043. (Pubitemid 41214296)
12. Chen L, Fischle W, Verdin E, Greene WC. (2001). Duration of nuclear NF-kappaB action regulated by reversible acetylation. Science 293: 1653-1657. (Pubitemid 32807844)
13. Chen YC, Chen JH, Richard K, Chen PY, Christiani DC. (2004b). Lung adenocarcinoma and human papillomavirus infection. Cancer 101: 1428-1436. (Pubitemid 39180399)
14. Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S et al. (2005). Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer. Clin Cancer Res 11: 7674-7682. (Pubitemid 41611609)
15. Denison MS, Nagy SR. (2003). Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol 43: 309-334. (Pubitemid 37372644)
16. Devesa SS, Bray F, Vizcaino AP, Parkin DM. (2005). International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising. Int J Cancer 117: 294-299. (Pubitemid 41379403)
17. Dhar A, Young MR, Colburn NH. (2002). The role of AP-1, NFkappaB and ROS/NOS in skin carcinogenesis: the JB6 model is predictive. Mol Cell Biochem 234-235: 185-193. (Pubitemid 34777856)
18. Dietrich C, Kaina B. (2010). The aryl hydrocarbon receptor (AhR) in the regulation of cell-cell contact and tumor growth. Carcinogenesis 31: 1319-1328.
19. Dijsselbloem N, Vanden Berghe W, De Naeyer A, Haegeman G. (2004). Soy isoflavone phyto-pharmaceuticals in interleukin-6 affections. Multi-purpose nutraceuticals at the crossroad of hormone replacement, anti-cancer and anti-inflammatory therapy. Biochem Pharmacol 68: 1171-1185. (Pubitemid 39094283)
20. DiNatale BC, Schroeder JC, Francey LJ, Kusnadi A, Perdew GH. (2010). Mechanistic insights into the events that lead to synergistic induction of interleukin 6 transcription upon activation of the aryl hydrocarbon receptor and inflammatory signaling. J Biol Chem 285: 24388-24397.
21. Fukuda I, Mukai R, Kawase M, Yoshida K, Ashida H. (2007). Interaction between the aryl hydrocarbon receptor and its antagonists, flavonoids. Biochem Biophys Res Commun 359: 822-827. (Pubitemid 46899026)
22. Gao SG, Dong XY, Wang LJ, He J. (2007). The study on the chromosome aneuploidy in human lung cancer]. Zhonghua Yi Xue Za Zhi 87: 1701-1703. (Pubitemid 47316240)
23. Hayashibara T, Yamada Y, Mori N, Harasawa H, Sugahara K, Miyanishi T et al. (2003). Possible involvement of aryl hydrocarbon receptor (AhR) in adult T-cell leukemia (ATL) leukemogenesis: constitutive activation of AhR in ATL. Biochem Biophys Res Commun 300: 128-134. (Pubitemid 36042940)
24. Ishida M, Mikami S, Kikuchi E, Kosaka T, Miyajima A, Nakagawa K et al. (2010). Activation of the aryl hydrocarbon receptor pathway enhances cancer cell invasion by upregulating the MMP expression and is associated with poor prognosis in upper urinary tract urothelial cancer. Carcinogenesis 31: 287-295.
25. Izawa H, Kohara M, Aizawa K, Suganuma H, Inakuma T, Watanabe G et al. (2008). Alleviative effects of quercetin and onion on male reproductive toxicity induced by diesel exhaust particles. Biosci Biotechnol Biochem 72: 1235-1241. (Pubitemid 351872496)
26. Jensen BA, Leeman RJ, Schlezinger JJ, Sherr DH. (2003). Aryl hydrocarbon receptor (AhR) agonists suppress interleukin-6 expression by bone marrow stromal cells: an immunotoxicology study. Environ Health 2: 16.
27. Kasai A, Hiramatsu N, Hayakawa K, Yao J, Maeda S, Kitamura M. (2006). High levels of dioxin-like potential in cigarette smoke evidenced by in vitro and in vivo biosensing. Cancer Res 66: 7143-7150. (Pubitemid 44197692)
28. Ke S, Rabson AB, Germino JF, Gallo MA, Tian Y. (2001). Mechanism of suppression of cytochrome P-450 1A1 expression by tumor necrosis factor-alpha and lipopolysaccharide. J Biol Chem 276: 39638-39644.
29. Kim DW, Gazourian L, Quadri SA, Romieu-Mourez R, Sherr DH, Sonenshein GE. (2000). The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 19: 5498-5506. (Pubitemid 32000917)
30. Liaw YP, Huang YC, Lien GW. (2005). Patterns of lung cancer mortality in 23 countries: application of the age-period-cohort model. BMC Public Health 5: 22.
31. Lin P, Chang H, Tsai WT, Wu MH, Liao YS, Chen JT et al. (2003). Overexpression of aryl hydrocarbon receptor in human lung carcinomas. Toxicol Pathol 31: 22-30. (Pubitemid 36169418)
32. Lin PH, Lin CH, Huang CC, Chuang MC, Lin P. (2007). 2,3,7,8- Tetrachlorodibenzo-p-dioxin (TCDD) induces oxidative stress, DNA strand breaks, and poly(ADP-ribose) polymerase-1 activation in human breast carcinoma cell lines. Toxicol Lett 172: 146-158. (Pubitemid 47189732)
33. Lu F, Zahid M, Wang C, Saeed M, Cavalieri EL, Rogan EG. (2008). Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev Res (Phila) 1: 135-145.
34. Matsumoto Y, Ide F, Kishi R, Akutagawa T, Sakai S, Nakamura M et al. (2007). Aryl hydrocarbon receptor plays a significant role in mediating airborne particulate-induced carcinogenesis in mice. Environ Sci Technol 41: 3775-3780. (Pubitemid 350067228)
35. Mukai M, Tischkau SA. (2007). Effects of tryptophan photoproducts in the circadian timing system: searching for a physiological role for aryl hydrocarbon receptor. Toxicol Sci 95: 172-181. (Pubitemid 44942787)
36. Oesch-Bartlomowicz B, Huelster A, Wiss O, Antoniou-Lipfert P, Dietrich C, Arand M et al. (2005). Aryl hydrocarbon receptor activation by cAMP vs dioxin: divergent signaling pathways. Proc Natl Acad Sci USA 102: 9218-9223. (Pubitemid 40923544)
37. Ohtake F, Baba A, Takada I, Okada M, Iwasaki K, Miki H et al. (2007). Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 446: 562-566. (Pubitemid 46514731)
38. Peng TL, Chen J, Mao W, Song X, Chen MH. (2009). Aryl hydrocarbon receptor pathway activation enhances gastric cancer cell invasiveness likely through a c-Jun-dependent induction of matrix metalloproteinase-9. BMC Cell Biol 10: 27.
39. Pollenz RS. (2002). The mechanism of AH receptor protein downregulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem Biol Interact 141: 41-61. (Pubitemid 35223204)
40. Puga A, Barnes SJ, Chang C, Zhu H, Nephew KP, Khan SA et al. (2000). Activation of transcription factors activator protein-1 and nuclear factor-kappaB by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem Pharmacol 59: 997-1005. (Pubitemid 30110816)
41. Scagliotti GV, Longo M, Novello S. (2009). Nonsmall cell lung cancer in never smokers. Curr Opin Oncol 21: 99-104.
42. Sharma D, Fondell JD. (2002). Ordered recruitment of histone acetyltransferases and the TRAP/Mediator complex to thyroid hormone-responsive promoters in vivo. Proc Natl Acad Sci USA 99: 7934-7939. (Pubitemid 34650983)
43. Shimba S, Komiyama K, Moro I, Tezuka M. (2002). Overexpression of the aryl hydrocarbon receptor (AhR) accelerates the cell proliferation of A549 cells. J Biochem 132: 795-802. (Pubitemid 35408504)
44. Smith PC, Hobisch A, Lin DL, Culig Z, Keller ET. (2001). Interleukin-6 and prostate cancer progression. Cytokine Growth Factor Rev 12: 33-40. (Pubitemid 32294585)
45. Su JM, Lin P, Wang CK, Chang H. (2009). Overexpression of cytochrome P450 1B1 in advanced non-small cell lung cancer: a potential therapeutic target. Anticancer Res 29: 509-515.
46. Subramanian J, Velcheti V, Gao F, Govindan R. (2007). Presentation and stage-specific outcomes of lifelong never-smokers with nonsmall cell lung cancer (NSCLC). J Thorac Oncol 2: 827-830. (Pubitemid 47361024)
47. Tan XL, Wang T, Xiong S, Kumar SV, Han W, Spivack SD. (2009). Smoking-related gene expression in laser capture-microdissected human lung. Clin Cancer Res 15: 7562-7570.
48. Thun MJ, Hannan LM, Adams-Campbell LL, Boffetta P, Buring JE, Feskanich D et al. (2008). Lung cancer occurrence in never-smokers: an analysis of 13 cohorts and 22 cancer registry studies. PLoS Med 5: e185.
49. Tian Y. (2009). Ah receptor and NF-kappaB interplay on the stage of epigenome. Biochem Pharmacol 77: 670-680.
50. Trikha M, Corringham R, Klein B, Rossi JF. (2003). Targeted antiinterleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence. Clin Cancer Res 9: 4653-4665. (Pubitemid 37323267)
51. Tse LA, Yu IT, Au JS, Yu KS, Kwok KP, Qiu H et al. (2009). Environmental tobacco smoke and lung cancer among Chinese nonsmoking males: might adenocarcinoma be the culprit? Am J Epidemiol 169: 533-541.
52. Vanden Berghe W, Dijsselbloem N, Vermeulen L, Ndlovu N, Boone E, Haegeman G. (2006). Attenuation of mitogen-and stress-activated protein kinase-1-driven nuclear factor-kappaB gene expression by soy isoflavones does not require estrogenic activity. Cancer Res 66: 4852-4862.
53. Wang CK, Chang H, Chen PH, Chang JT, Kuo YC, Ko JL et al. (2009a). Aryl hydrocarbon receptor activation and overexpression upregulated fibroblast growth factor-9 in human lung adenocarcinomas. Int J Cancer 125: 807-815.
54. Wang XR, Yu IT, Chiu YL, Qiu H, Fu Z, Goggins W et al. (2009b). Previous pulmonary disease and family cancer history increase the risk of lung cancer among Hong Kong women. Cancer Causes Control 20: 757-763.
55. Whitlock Jr JP. (1999). Induction of cytochrome P4501A1. Annu Rev Pharmacol Toxicol 39: 103-125. (Pubitemid 29222553)
56. Yu IT, Chiu YL, Au JS, Wong TW, Tang JL. (2006). Dose-response relationship between cooking fumes exposures and lung cancer among Chinese nonsmoking women. Cancer Res 66: 4961-4967.
57. Zerbini LF, Wang Y, Cho JY, Libermann TA. (2003). Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206-2215. (Pubitemid 36538628)